Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis

BMC Pulmonary Medicine

Table 2 S.pyogenes sputum isolates and exacerbation status in adult cystic fibrosis patients

Isolate	Patient^a	Date of Isolation	CFU^b	GAS Most Abundant	Reduced FEV₁ ^c	PEx^d	Chronic Bacterial Infections
1	1	08-1997	10⁶	N	N	N	PA
2	2	04-2010	10⁴	N	Y	Y^a	None
3	3	08-2013	10⁴	Y	N/I	Y	None
4	4	09-2010	10⁶	Y	N	N	PA, MSSA
5	5	09-2010	10⁷	Y	N/I	Y	MSSA, HI
6	6	12-2001	10⁷	Y	N	N	MSSA
7	6	02-2002	10⁷	Y	N	N	None
8	6	05-2002	10⁷	Y	N	Y^a	None
9	7	07-2006	10⁷	Y	Y	Y	MSSA, HI
10	8	07-2012	10⁵	N	N	N	PA
11	9	10-1995	10⁸	Y	N	Y^a	MSSA, HI
12	10	05-1999	10⁷	N	N	N	MSSA, Bc
13	11	01-2001	10⁷	Y	N	N	MSSA
14	12	10-2012	10⁵	Y	N	N	PA
15	13	11-2012	10⁶	Y	N	Y	PA
16	14	11-2006	10⁷	Y	N	N	PA, MSSA
17	15	10-2000	10⁶	N	N	N	PA, MSSA
18	15	11-2002	10⁵	N	N	Y	None
19	15	02-2009	10⁶	N	N	Y	None
20	15	05-2009	10³	N	N	N	None

^a Refer to Table 1
^b CFU colony forming units/ml of sputum
^c Reduced FEV1 reduction in reduction in FEV₁ by >10% at time of visit compared to baseline FEV₁
^d PEx pulmonary exacerbation as defined by Fuch’s Criteria and the need for antibiotics
^* Severe PEx pulmonary exacerbation requiring hospitalization and/or parenteral antibiotics
^e PA Pseudomonas aeruginosa, MSSA Methicillin sensitive S. aureus, HI Haemophilus influenzae, Bc Burkholderia cenocepacia
Y yes, N no, N/I no information, N/I no information

ISSN: 1471-2466